Is Aligos Therapeutics, Inc. (ALGS) a Buy, Sell, or Hold?
Aligos Therapeutics, Inc.
NASDAQ:ALGS
$6.105 USD
-$0.26 (-4.01%)
- Volume
- 102.51K
- Average Volume
- 289.73K
- Market Capitalization
- $37.78M
- P/E Ratio
- -0.70
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $13.69
- Year Low
- $4.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.56
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Lawrence Blatt |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALGS |
| CUSIP | 01626L204 |
| CIK | 0001799448 |
| Web | https://www.aligos.com |
| Phone | 800 466 6059 |
| Currency | USD |
| Employees | 82 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.14 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.56 |
| Quick Ratio | 2.56 |
| Cash Ratio | 1.29 |
Sales & Book Value
| Annual Sales | $2.19M |
| Price / Sales | 8.03 |
| Cash Flow | -8.19 |
| Price / Cash Flow | -0.44 |
| Price / Book | 2.00 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $20.00 |
| Forecast Upside/Downside | -69.48% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.45 |
| Trailing P/E Ratio | -0.70 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-24.19M |
| Net Margin | -1919.68% |
| Pretax Margin | -1907.18% |
| Return on Equity | -139.47% |
| Return on Assets | -139.91% |
Financials Score
| AltmanZ Score | -17.54 |
| Piotroski Score | 2.00 |
| Working Capital | 36.31M |
| Total Assets | 64.56M |
| Ebit | -89.73M |
| Market Cap | 39.36M |
| Total Liabilities | 32.77M |
Poll Results
About Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from H ... BV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
2026-07-13 08:00:00
SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir sodium, under development for the treatment of chronic hepatitis B virus (HBV) infection.
2026-07-06 16:05:00
Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech Co., Ltd.
2026-06-14 17:00:00
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
2026-06-04 09:00:00
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgiser
2026-05-30 12:00:00
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
2026-05-27 02:30:00
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented 40% of HBeAgparticipants with chronic HBV infection treated with pevifoscorvir sodium at week 48 had reductions in HBsAg that would potentially allow them to qualify for ASO treatment SOUTH SAN FRANCISCO, Calif.
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
2026-05-27 02:30:00
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from ten presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain.
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
2026-05-13 02:05:00
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.
Frequently Asked Questions
-
What is the current Aligos Therapeutics, Inc. (ALGS) stock price?
-
Aligos Therapeutics, Inc.(NASDAQ:ALGS) stock price is $6.105 in the last trading session. During the trading session, ALGS stock reached the peak price of $13.689 while $4.8 was the lowest point it dropped to. The percentage change in ALGS stock occurred in the recent session was --4.01% while the dollar amount for the price change in ALGS stock was -$-0.26.
-
ALGS's industry and sector of operation?
-
The NASDAQ listed ALGS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALGS?
-
David Smith | Executive Vice President & Head of Chemical Operations
Julian A. Symons DPHIL | Executive Vice President & Chief Scientific Officer
Kieron Wesson | Vice President & Head of Chemistry Manufacturing Controls
Lawrence Blatt | Chief Executive Officer, President & Chairman of the Board
Tse-I Lin | Senior Vice President of Early Compound Development & Belgian Site Head -
How many employees does ALGS have?
-
Number of ALGS employees currently stands at 82. ALGS operates from One Corporate Drive, South San Francisco, CA 94080, US.
-
Link for ALGS official website?
-
Official Website of ALGS is: https://www.aligos.com
-
How do I contact ALGS?
-
ALGS could be contacted at phone #800 466 6059 and can also be accessed through its website. ALGS operates from One Corporate Drive, South San Francisco, CA 94080, US.
-
How many shares of ALGS are traded daily?
-
The average number of ALGS shares traded daily for last 3 months was 289.73K.
-
What is the market cap of ALGS currently?
-
The market value of ALGS currently stands at $37.78M with its latest stock price at $6.105